Add to Favourites
To login click here
This article discusses a research collaboration between the University of Delaware and Nemours Children’s Health that used artificial intelligence to identify the most effective drug therapies for patients with acute myeloid leukemia (AML). The research was published in the journal Bioinformatics Advances and is a step forward in the drive towards precision medicine. AML affects both children and adults and is an aggressive blood cancer with a five-year survival rate of 31.7%. Machine learning was used to determine if a person with AML will be a “high responder” or a “low responder” to any of 100 different drug therapies.
